What caused the drop in 4894.T stock today?

The intraday drop to **JPY 6740.00** on 03 Mar 2026 reflected profit-taking and attention to recent company metrics. Reuters coverage and higher volume (**487,400.00**) amplified selling. No single regulatory update was cited in the session.

What is Meyka's view on 4894.T stock?

Meyka AI rates 4894.T **69.08/100 (Grade B, HOLD)**. The model shows a 12-month projection of **JPY 9613.48**, implying **42.61%** upside. This grade factors in benchmarks, sector, financial growth, metrics, and consensus.

Is 4894.T stock cheap on valuation metrics?

Not by standard measures. Cuorips posts **EPS -81.61** and **PE -90.06**, with price-to-book **12.09** and price-to-sales **170.36**, signalling high valuation relative to Healthcare peers and elevated risk.

What technical levels should traders watch for 4894.T stock?

Key levels: support at the day low **JPY 6740.00**, resistance near the 50-day average **JPY 7647.80**, and the 200-day average **JPY 6765.10**. RSI sits at **42.86**, so momentum remains negative but not deeply oversold.

JP Stocks

4894.T stock drops 16.58% to JPY 6740 on 03 Mar 2026 JPX close: catalyst watch

ByDanny Kontos March 3, 2026March 3, 2026

The 4894.T stock plunged 16.58% to JPY 6740.00 at the JPX close on 03 Mar 2026, marking a heavy intraday move on higher volume. Trading hit 487,400.00 shares versus a 50-day average of 283,396.00, sending the biotech name sharply lower. Shares opened at JPY 7450.00 and traded as high as JPY 7460.00 before collapsing to the day low. Investors cite weaker near-term outlook and profit-taking after recent gains.